Diabetic nephropathy: introduction.
Breyer
Matthew D
MD
Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D018384:Oxidative Stress; D011379:Prognosis; D017382:Reactive Oxygen Species / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D017382:Reactive Oxygen Species